Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity
Li Y, Chen H, Li S, Li Y, Liu G, Bai J, et al
Regardless of mechanism, clinical observations support a nausea-reducing effect in a subset of users
What's Coming: GLP-1 Medications in Development for 2026 For patients evaluating their options heading into the new year, understanding the near-term pipeline provides useful context for decision-making: Oral Options Expanding: On December 22, 2025, Novo Nordisk announced that the FDA approved oral Wegovy for chronic weight management
US$ 29.31
US$ 26.71
US$ 28.51
US$ 27.47
US$ 23.91
